目的 分析2015-2018年浙江省12家醫(yī)院腫瘤患者抗凝藥物的使用現(xiàn)狀及其用藥特點(diǎn)和趨勢。方法 對2015-2018年浙江省12家醫(yī)院腫瘤患者使用的抗凝藥物的用藥金額、用藥頻度（DDDs）、限定日費(fèi)用（DDC）及排序比（B/A）等情況進(jìn)行統(tǒng)計分析。結(jié)果 2015-2018年腫瘤患者抗凝藥物的用藥總金額呈上升趨勢，2018年比2015年上漲2倍左右；其中肝素類抗凝藥的DDDs和DDC排名較前，肝素鈉類B/A大于或接近于1，肝素鈣類B/A小于1；新型口服抗凝藥利伐沙班片、阿哌沙班片和達(dá)比加群酯膠囊的DDDs逐年上漲，但排名仍較后，且DDC較高，B/A接近于1；纖溶藥的DDDs輕微上升，但DDC較為穩(wěn)定，B/A小于1；華法林的DDDs穩(wěn)定，DDC低廉，B/A大于1。結(jié)論 2015-2018年浙江省12家醫(yī)院腫瘤患者抗凝藥物的使用基本合理，基本無濫用情況。

Objective To analysis the current situation and the characteristic and tendency of anticoagulants used in cancer patients in Zhejiang Province. Methods The prescriptions data of cancer patients in 12 hospitals of Zhejiang Province from 2015 to 2018 were statistically analyzed, including the consumption, frequency of drug use (DDDs), defined daily cost (DDC) and drug sequence ratio (B/A). Results The consumption of anticoagulants showed an overall increased trend in 2018 compared to 2015 and it increased about twice in 2018 as much as in 2015. DDDs and DDC of heparin anticoagulants ranked higher, and B/A of heparin sodium was larger or close to 1 while the heparin calcium is less than 1. DDDs of the new oral anticoagulants including rivaroxaban, apixaban and dabigatran increased year by year while the ranking were still lower, and DDC was higher, meanwhile B/A were close to 1. DDDs of fibrinolytic drugs slight increased while DDC were stable, and B/A was less than 1. Warfarin has a stable frequency, low daily cost, and B/A were ratio greater than 1. Conclusions The utilization of anticoagulants varieties used by cancer patients was generally reasonable in 12 hospitals of Zhejiang Province from 2015 to 2018, basically no abuse.

R973

浙江省自然科學(xué)基金資助項目（LQ15H020001）